Liver transplantation for hepatocellular carcinoma.
In patients with cirrhosis and hepatocellular carcinoma (HCC), orthotopic liver transplantation (OLT) offers hope for cure of both the complicating HCC and the underlying chronic liver disease. Excellent 5 year survival has been reported when the restrictive Milan criteria are used to select transplant candidates. Alternative recommendations have recently been proposed by groups at University of California San Francisco, University of Pittsburgh and Mount Sinai. We review current and evolving concepts regarding selection criteria for OLT in patients with HCC, along with strategies to reduce waiting times, such as the impact of the implementation of the model for end-stage liver disease (MELD) scoring system on organ distribution and the role of living donor OLT for this indication. The possible efficacy of adjuvant anti-tumour therapies in limiting HCC growth while waiting for OLT, along with factors influencing the risk of HCC recurrence post-OLT, the major cause of death in this setting, are also discussed.
Kurtovic
Jelica
J
Gastrointestinal and Liver Unit, The Prince of Wales Hospital and University of New South Wales, Sydney, NSW, Australia.
Riordan
Stephen M
SM
Williams
Roger
R
D006528:Carcinoma, Hepatocellular / Q000601:surgery*; D018450:Disease Progression; D006801:Humans; D008113:Liver Neoplasms / Q000601:surgery*; D016031:Liver Transplantation; D019656:Loss of Heterozygosity; D009361:Neoplasm Invasiveness; D018579:Patient Selection; D009927:Tissue and Organ Procurement